Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis

Oncogene

Volumn 23, Issue 28, 2004, Pages 4862-4872

  Spierings, Diana C J ^a   De Vries, Elisabeth G E ^a   Stel, Alja J ^a   Te Rietstap, Nelina ^a   Vellenga, Edo ^a   De Long, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cisplatin; Fas; Irradiation; p21; TGCT

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; FAS ANTIGEN; MESSENGER RNA; PROTEASOME; PROTEIN P21; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PRIMER DNA;

APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL LEVEL; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GERM CELL TUMOR; HUMAN; HUMAN CELL; IRRADIATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS; TUMOR CELL; CELL CYCLE; CELL DEATH; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS TUMOR; TUMOR CELL LINE;

ANTIGENS, CD95; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TESTICULAR NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 3042850560     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207617     Document Type: Article

References (78)

1. Agami R, Blandino G, Oren M and Shaul Y. (1999). Nature, 399, 809-813.
2. Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR. (1998). J. Biol. Chem., 273, 1-4.
3. Arriola EL, Rodriguez-Lopez AM, Hickman JA and Chresta CM. (1999). Oncogene, 18, 1457-1464.
4. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K and Mizutani S. (1999). EMBO J., 18, 1223-1234.
5. Bartkova J, Thullberg M, Rajpert-de Meyts E, Skakkebaek NE and Bartek J. (2000). Int. J. Cancer, 85, 370-375.
6. Burger H, Nooter K, Boersma AW, Kortland CJ and Stoter G. (1997). Int. J. Cancer, 73, 592-599.
7. Burger H, Nooter K, Boersma AW, Kortland CJ and Stoter G. (1998a). Br. J. Cancer, 77, 1562-1567.
8. Burger H, Nooter K, Boersma AW, Kortland CJ, van den Berg AP and Stoter G. (1998b). Int. J. Radiat. Oncol. Biol. Phys., 41, 415-424.
9. Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG and Stoter G. (1999). Int. J. Cancer, 81, 620-628.
10. Butz K, Geisen C, Ullmann A, Zentgraf H and Hoppe-Seyler F. (1998). Oncogene, 17, 781-787.
11. Chang HY, Nishitoh H, Yang X, Ichijo H and Baltimore D. (1998). Science, 281, 1860-1863.
12. Charette SJ, Lavoie JN, Lambert H and Landry J. (2000). Mol. Cell Biol., 20, 7602-7612.
13. Chresta CM, Masters JR and Hickman JA. (1996). Cancer Res., 56, 1834-1841.
14. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y and Firestone GL. (1998). J. Biol. Chem., 273, 2008-2014.
15. Datta MW, Macri E, Signoretti S, Renshaw AA and Loda M. (2001). Mod. Pathol., 14, 437-442.
16. De Jong S, Timmer-Bosscha H, de Vries EG and Mulder NH. (1993). Int. J. Cancer, 53, 110-117.
17. De Jong S, van Zanten J, Dam WA, Mulder NH and de Vries EG. (1999). Proc. Am. Assoc. Cancer Res., 40, 4588.
18. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS and Reed JC. (1999). EMBO J., 18, 5242-5251.
19. Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosova I, Kulans LA, Fu X, Weinberg JS, Heinecke JW, Roth KA and Weintraub SJ. (2002). Cell, 111, 51-62.
20. Dijkhuizen T, Van den Berg E, Van den Berg A, Storkel S, De Jong B, Seitz G and Henn W. (1996). Int. J. Cancer, 68, 47-50.
21. Einhorn LH. (2002). Proc. Natl. Acad. Sci. USA, 99, 4592-4595.
22. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B. (1994). Cancer Res., 54, 1169-1174.
23. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. (1993). Cell, 75, 817-825.
24. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T. (2001a). Nature, 411, 494-498.
25. Elbashir SM, Lendeckel W and Tuschl T. (2001b). Genes Dev., 15, 188-200.
26. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF and Khanna KK. (2001). Oncogene, 20, 514-522.
27. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME and Debatin KM. (1998). Cell Death Differ., 5, 884-893.
28. Gervais JL, Seth P and Zhang H. (1998). J. Biol. Chem., 273, 19207-19212.
29. Glaser T, Wagenknecht B and Weller M. (2001). Oncogene, 20, 4757-4767.
30. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M and Wang JY. (1999). Nature, 399, 806-809.
31. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC and Holbrook NJ. (1997). Oncogene, 14, 929-935.
32. Greenblatt MS, Bennett WP, Hollstein M and Harris CC. (1994). Cancer Res., 54, 4855-4878.
33. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De LV, Fey MF, Melino G and Tobler A. (2001). Cell Death Differ., 8, 1213-1223.
34. Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, Iggo R, Gray AC, Jichlinski P, Leisinger HJ and Benhattar J. (1996). Am. J. Pathol., 149, 1221-1228.
35. Hara S, Miyake H, Nakamura I, Arakawa S, Kamidono S and Hara I. (2001). Urology, 58, 471-476.
36. Hiyama H, Iavarone A and Reeves SA. (1998). Oncogene, 16, 1513-1523.
37. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ and Chaganti RS. (1998). Oncogene, 16, 2345-2349.
38. Huddart RA, Titley J, Robertson D, Williams GT, Horwich A and Cooper CS. (1995). Eur. J. Cancer, 31A, 739-746.
39. Johnstone RW. (2002). Mol. Cell, 10, 695-697.
40. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C and Looijenga LH. (2002a). J. Clin. Oncol., 20, 1551-1561.
41. Kersemaekers AM, van Weeren PC, Oosterhuis JW and Looijenga LH. (2002b). J. Pathol., 196, 423-429.
42. Kimura K and Gelmann EP. (2000). J. Biol. Chem., 275, 8610-8617.
43. Ko YG, Kang YS, Park H, Seol W, Kim J, Kim T, Park HS, Choi EJ and Kim S. (2001). J. Biol. Chem., 276, 39103-39106.
44. Levine AJ. (1997). Cell, 88, 323-331.
45. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM and Ross R. (1998). Mol. Cell, 1, 553-563.
46. Levrero M, De LV, Costanzo A, Gong J, Wang JY and Melino G. (2000). J. Cell Sci., 113 (Part 10), 1661-1670.
47. Lundberg AS and Weinberg RA. (1999). Eur. J. Cancer, 35, 1886-1894.
48. Lutzker SG. (1998). APMIS, 106, 85-89.
49. Lutzker SG. Mathew R and Taller DR. (2001). Oncogene, 20, 2982-2986.
50. Malashicheva AB, Kislyakova TV, Aksenov ND, Osipov KA and Pospelov VA. (2000). Oncogene, 19, 3858-3865.
51. Masters JR, Osborne EJ, Walker MC and Parris CN. (1993). Int. J. Cancer, 53, 340-346.
52. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D. (1994). Cancer Res., 54, 3391-3395.
53. Naujokat C and Hoffmann S. (2002). Lab. Invest., 82, 965-980.
54. Ogawa Y, Nishioka A, Kubonishi II, Inomata T, Yoshida S and Kataoka S. (1998). Int. J. Mol. Med., 2, 435-436.
55. Prives C and Hall PA. (1999). J. Pathol., 187, 112-126.
56. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C and Levine AJ. (1995). Mol. Carcinog., 12, 124-131.
57. Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH and de Vries EG. (1995). Br. J. Cancer, 71, 684-690.
58. Scaffidi C, Schmitz I, Krammer PH and Peter ME. (1999). J. Biol. Chem., 274, 1541-1548.
59. Schepers H, Geugien M, Eggen BJL and Vellenga E. (2003). Leukemia, 17, 2113-2121.
60. Sheard MA, Krammer PH and Zaloudik J. (1999). Br. J. Cancer, 80, 1689-1696.
61. Shen Y and White E. (2001). Adv. Cancer Res., 82, 55-84.
62. Skilling JS, Squatrito RC, Connor JP, Niemann T and Buller RE. (1996). Gynecol. Oncol., 60, 72-80.
63. Snowden AW, Anderson LA, Webster GA and Perkins ND. (2000). Mol. Cell. Biol., 20, 2676-2686.
64. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL and El-Deiry WS. (1997). Nature, 389, 187-190.
65. Spierings DCJ, de Vries EGE, Vellenga E and de Jong S. (2003a). Cell Death Differ., 10, 808-822.
66. Spierings DCJ, de Vries EGE, Vellenga E and de Jong S. (2003b). J. Pathol., 200, 137-148.
67. Stiewe T, Theseling CC and Putzer BM. (2002). J. Biol. Chem., 277, 14177-14185.
68. Sugihara A, Saiki S, Tsuji M, Tsujimura T, Nakata Y, Kubota A, Kotake T and Terada N. (1997). Anticancer Res., 17, 3861-3865.
69. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K. Nakano T, Miura M and Shiraki K. (2000a). Oncogene, 19, 1346-1353.
70. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y and Akahane K. (2000b). Cell Death Differ., 7, 721-728.
71. Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T and Akahane K. (1999). Mol. Cell Biol., 19, 3842-3847.
72. Tsai KKC and Yuan ZM. (2003). Cancer Res., 63, 3418-3424.
73. Vikhanskaya F, D'Incalci M and Broggini M. (2000). Nucleic Acids Res., 28, 513-519.
74. Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J and Escandon E. (2002). Oncogene, 21, 3611-3619.
75. Xu SQ and El-Deiry WS. (2000). Biochem. Biophys. Res. Commun., 269, 179-190.
76. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E and Moll UM. (2002). J. Exp. Med., 196, 765-780.
77. Zeng YX, Somasundaram K and El-Deiry WS. (1997). Nat. Genet., 15, 78-82.
78. Zhang Y, Fujita N and Tsuruo T. (1999). Oncogene, 18, 1131-1138.